Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Abemaciclib (LY2835219) Plus Fulvestrant sammenlignet med Placebo Plus Fulvestrant i tidligere behandlet brystkræft (postMONARCH)

3. oktober 2026 opdateret af: Eli Lilly and Company

postMONARCH: Et randomiseret, dobbeltblindt, placebokontrolleret, fase 3-studie for at sammenligne effektiviteten af ​​Abemaciclib Plus Fulvestrant med Placebo Plus Fulvestrant hos deltagere med HR+, HER2-, avanceret eller metastatisk brystkræft efter progression på en CDK4 & 6-hæmmer og endokrin Terapi

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

368

Fase

  • Fase 3

Udvidet adgang

Godkendt til salg til offentligheden. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • San Juan, Argentina, 5400
        • CER San Juan
    • Buenos Air
      • Buenos Aires, Buenos Air, Argentina, C1426ABP
        • Fundación Respirar
      • Ciudad Autónoma de Buenos Aire, Buenos Air, Argentina, C1027AAP
        • Centro de Investigaciones Metabólicas (CINME)
    • Buenos Aires F.D.
      • CABA, Buenos Aires F.D., Argentina, 1125
        • Fundación Cenit Para La Investigación En Neurociencias
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Argentina, 5800
        • Instituto Médico Río Cuarto
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Centro Medico San Roque
      • Namur, Belgien, 5000
        • CHU UCL Namur/Site Sainte Elisabeth
    • Antwerpen
      • Brasschaat, Antwerpen, Belgien, 2930
        • Algemeen Ziekenhuis klina
    • Limburg
      • Hasselt, Limburg, Belgien, 3500
        • Jessa Ziekenhuis
    • Capital Region
      • Copenhagen, Capital Region, Danmark, 2730
        • Herlev and Gentofte Hospital
    • Central Jutland
      • Herning, Central Jutland, Danmark, 7400
        • Regionshospitalet Gødstrup
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85004
        • St. Joseph's Hospital and Medical Center
    • Arkansas
      • Springdale, Arkansas, Forenede Stater, 72762
        • Highlands Oncology Group
    • California
      • Fullerton, California, Forenede Stater, 92835
        • Providence Medical Foundation
      • Los Alamitos, California, Forenede Stater, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Forenede Stater, 90033
        • Keck School of Medicine of USC
      • Los Angeles, California, Forenede Stater, 90024
        • TRIO-US (Translational Research in Oncology-US)
      • Santa Monica, California, Forenede Stater, 90404
        • UCLA Hematology/Oncology - Parkside
      • Sylmar, California, Forenede Stater, 91342
        • Olive View-UCLA Medical Center
      • Torrance, California, Forenede Stater, 90505
        • Torrance Memorial Physician Network / Cancer Care
      • Whittier, California, Forenede Stater, 90602
        • PIH Health Hematology Medical Oncology
    • Colorado
      • Denver, Colorado, Forenede Stater, 80220
        • Rocky Mountain Cancer Center - Hale Parkway
    • Florida
      • Fort Myers, Florida, Forenede Stater, 33901-8101
        • Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
      • Hollywood, Florida, Forenede Stater, 33024
        • Millennium Oncology Research Clinic
      • Miami, Florida, Forenede Stater, 33136
        • University of Miami Hospital and Clinics, Sylvester Cancer Center
      • Pensacola, Florida, Forenede Stater, 32503
        • Woodlands Medical Specialists, PA
      • Sarasota, Florida, Forenede Stater, 34232
        • Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
      • West Palm Beach, Florida, Forenede Stater, 33401
        • Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Winship Cancer Institute, Emory University
      • Gainesville, Georgia, Forenede Stater, 30501
        • Northeast Georgia Medical Center
      • Macon, Georgia, Forenede Stater, 31201
        • Central Georgia Cancer Care
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96826
        • Kapiolani Medical Center for Women and Children
    • Illinois
      • Harvey, Illinois, Forenede Stater, 60426
        • Ingalls Memorial Hospital
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater, 70809
        • Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
      • Lake Charles, Louisiana, Forenede Stater, 70601
        • Clinical Trials of SWLA
    • Maine
      • Lewiston, Maine, Forenede Stater, 04240
        • Central Maine Medical Center
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21237
        • Mfsmc-Hjwci
      • Clinton, Maryland, Forenede Stater, 20735
        • Maryland Oncology Hematology, P.A. - Clinton
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forenede Stater, 02215
        • Dana Farber Cancer Institute
      • Danvers, Massachusetts, Forenede Stater, 01923
        • MGH Northshore Cancer Center
      • Fairhaven, Massachusetts, Forenede Stater, 02719
        • Southcoast Centers for Cancer Care
      • Foxborough, Massachusetts, Forenede Stater, 02035
        • Dana-Farber Cancer Institute - Foxborough
      • Methuen, Massachusetts, Forenede Stater, 01844
        • Dana Farber Cancer Center Merrimack Valley
      • Milford, Massachusetts, Forenede Stater, 01757
        • Dana Farber Cancer Institute
      • Newton, Massachusetts, Forenede Stater, 02462
        • Mass General Cancer Center
      • South Weymouth, Massachusetts, Forenede Stater, 02190
        • Dana Farber Cancer Institute
      • Worcester, Massachusetts, Forenede Stater, 01606
        • Reliant Medical Group
    • Montana
      • Billings, Montana, Forenede Stater, 59102
        • St. Vincent Frontier Cancer Center
    • New Hampshire
      • Londonderry, New Hampshire, Forenede Stater, 03053
        • Dana Farber Cancer Center Londonderry
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • University of New Mexico Comprehensive Cancer Center
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02906
        • Lifespan Cancer Institute
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37404
        • Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
      • Nashville, Tennessee, Forenede Stater, 37203
        • Sarah Cannon Research Institute/SCRI
      • Nashville, Tennessee, Forenede Stater, 37203
        • Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
    • Texas
      • Bedford, Texas, Forenede Stater, 76022
        • Texas Oncology - Bedford
      • Denton, Texas, Forenede Stater, 76201
        • Texas Oncology - Denton
      • El Paso, Texas, Forenede Stater, 79902
        • Texas Oncology, P.A.
      • Houston, Texas, Forenede Stater, 77030-4009
        • University of Texas MD Anderson Cancer Center
      • McKinney, Texas, Forenede Stater, 75071
        • Texas Oncology - McKinney
      • McKinney, Texas, Forenede Stater, 75071
        • Woodlands Medical Specialists, PA
      • Mesquite, Texas, Forenede Stater, 75150
        • Woodlands Medical Specialists, PA
      • Plano, Texas, Forenede Stater, 75093
        • Texas Oncology-Plano West
      • Plano, Texas, Forenede Stater, 75075-7787
        • Texas Oncology - Plano East
      • San Antonio, Texas, Forenede Stater, 78229
        • Mays Cancer Center
      • The Woodlands, Texas, Forenede Stater, 77380
        • US Oncology
      • Tyler, Texas, Forenede Stater, 75702
        • Texas Oncology - Tyler Cancer Center
    • Utah
      • Murray, Utah, Forenede Stater, 84107
        • Intermountain Medical Center
      • St. George, Utah, Forenede Stater, 84790
        • Intermountain Healthcare - St. George
    • Vermont
      • Burlington, Vermont, Forenede Stater, 05401
        • The University of Vermont Medical Center Inc.
    • Virginia
      • Winchester, Virginia, Forenede Stater, 22601
        • Shenandoah Oncology, P.C.
    • Aquitaine
      • Bordeaux, Aquitaine, Frankrig, 33076
        • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    • Finistère
      • Brest, Finistère, Frankrig, 29609
        • CHRU de Brest
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, Frankrig, 44277
        • Hôpital privé du Confluent SAS
    • Vendée
      • La Roche-sur-Yon, Vendée, Frankrig, 85000
        • CHD Vendee
      • Thessaloniki, Grækenland, 546 45
        • Euromedica General Clinic of Thessaloniki
    • Achaḯa
      • Pátrai, Achaḯa, Grækenland, 26504
        • University Hospital of Patras
    • Attikí
      • Athens, Attikí, Grækenland, 115 28
        • Alexandra Hospital
    • Irakleío
      • Heraklion, Irakleío, Grækenland, 711 10
        • University General Hospital of Heraklion
    • Central District
      • Kfar Saba, Central District, Israel, 4428164
        • Meir Medical Center
      • Petah Tikva, Central District, Israel
        • Rabin Medical Center
      • Ramat Gan, Central District, Israel, 5265601
        • Sheba Medical Center
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 9112001
        • Hadassah Medical Center
    • Southern District
      • Beersheba, Southern District, Israel, 8400000
        • Soroka Medical Center
    • Tell Abīb
      • Tel Aviv, Tell Abīb, Israel, 6423906
        • Sourasky Medical Center
      • Bari, Italien, 70124
        • Instituto Tumori Giovanni Paolo II
      • Grosseto, Italien, 58100
        • Ospedale Misericordia di Grosseto
      • Milan, Italien, 20132
        • Ospedale San Raffaele
      • Viterbo, Italien, 01100
        • ASL Viterbo Ospedale Belcolle
    • Catania
      • Misterbianco, Catania, Italien, 95045
        • Humanitas Istituto Clinico Catanese
    • Emilia-Romagna
      • Meldola, Emilia-Romagna, Italien, 47014
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
    • Friuli Venezia Giulia
      • Udine, Friuli Venezia Giulia, Italien, 33100
        • P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
    • Estado de Baja California
      • Mexicali, Estado de Baja California, Mexico, 21200
        • Centro de Investigacion en Artritis y Osteoporosis SC
      • Tijuana, Estado de Baja California, Mexico, 22010
        • COI Tijuana - Centro Oncológico Internacional
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 45647
        • Centro Oncológico Internacional (COI)
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64060
        • Centro Regiomontano de Investigación
    • San Luis Potosí
      • San Luis Potosí City, San Luis Potosí, Mexico, 78209
        • Oncologico Potosino, S.C.
    • Masovian Voivodeship
      • Otwock, Masovian Voivodeship, Polen, 05-400
        • Europejskie Centrum Zdrowia - Oddzial Onkologii
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Polen, 45-060
        • Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
      • Badajoz, Spanien, 06006
        • Hospital Infanta Cristina
      • Madrid, Spanien, 28009
        • Hospital General Universitario Gregorio Marañon
      • Toledo, Spanien, 45007
        • Hospital Universitario de Toledo
    • A Coruña [La Coruña]
      • A Coruña, A Coruña [La Coruña], Spanien, 15006
        • CHUAC-Hospital Teresa Herrera
    • Balears [Baleares]
      • Palma, Balears [Baleares], Spanien, 07120
        • Hospital Universitari Son Espases
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Spanien, 08003
        • Parc de Salut Mar - Hospital del Mar
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spanien, 08036
        • Hospital Clínic de Barcelona
    • Murcia, Región de
      • El Palmar, Murcia, Región de, Spanien, 30120
        • Hospital Clínico Universitario Virgen de la Arrixaca
    • Málaga
      • Málaga, Málaga, Spanien, 29011
        • H.R.U Málaga - Hospital Materno-infantil
    • Navarre
      • Pamplona, Navarre, Spanien, 31009
        • Complejo Hospitalario de Navarra
    • Tarragona [Tarragona]
      • Reus, Tarragona [Tarragona], Spanien, 43204
        • Hospital Universitari Sant Joan de Reus
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Spanien, 46017
        • Hospital Universitario Doctor Peset
    • Stockholms
      • Stockholm, Stockholms, Sverige, 171 76
        • Karolinska Universitetssjukhuset Solna
    • Örebro Län [se-18]
      • Örebro, Örebro Län [se-18], Sverige, 701 85
        • Universitetssjukhuset Örebro
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Sydkorea, 13620
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [Seoul]
      • Seoul, Seoul-teukbyeolsi [Seoul], Sydkorea, 02841
        • Korea University Anam Hospital
      • Seoul, Seoul-teukbyeolsi [Seoul], Sydkorea, 08308
        • Korea University Guro Hospital
    • Taegu-Kwangyǒkshi
      • Daegu, Taegu-Kwangyǒkshi, Sydkorea, 41404
        • Kyungpook National University Chilgok Hospital
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Hospital
      • New Taipei City, Taiwan, 231
        • Taipei Tzu Chi General Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taipei, Taiwan, 10449
        • Mackay Memorial Hospital
      • Taoyuan, Taiwan, 333
        • Chang Gung Medical Foundation-Linkou Branch
    • Tainan
      • Tainan, Tainan, Taiwan, 71004
        • Chi Mei Medical Center
      • Hradec Králové, Tjekkiet, 500 05
        • Fakultni nemocnice Hradec Kralove
    • Pardubice Region
      • Pardubice, Pardubice Region, Tjekkiet, 53203
        • Multiscan
      • Adana, Tyrkiet (Türkiye), 01370
        • Adana City Hospital
      • Ankara, Tyrkiet (Türkiye), 06520
        • Memorial Ankara Hastanesi
      • Ankara, Tyrkiet (Türkiye), 06010
        • Ankara Gülhane Eitim ve Aratrma Hastanesi
      • Diyarbakır, Tyrkiet (Türkiye), 21200
        • Dicle Üniversitesi
      • Edirne, Tyrkiet (Türkiye), 22030
        • Trakya University
      • Istanbul, Tyrkiet (Türkiye), 34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Malatya, Tyrkiet (Türkiye), 44280
        • İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
    • Konya
      • Meram, Konya, Tyrkiet (Türkiye), 42080
        • Necmettin Erbakan Meram Medical Fac.
    • İzmir
      • Cordaleo, İzmir, Tyrkiet (Türkiye), 009035575
        • Izmir Medical Park Hospital
      • Budapest, Ungarn, 1122
        • Országos Onkológiai Intézet
      • Budapest, Ungarn, 1062
        • Magyar Honvedseg Egeszsegugyi Kozpont
    • Bács-Kiskun county
      • Kecskemét, Bács-Kiskun county, Ungarn, 6000
        • Bacs-Kiskun Megyei Korhaz
    • Győr-Moson-Sopron
      • Győr, Győr-Moson-Sopron, Ungarn, 9024
        • Petz Aladar Egyetemi Oktato Korhaz

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer

  • Have radiologic evidence of disease progression or recurrence either

    • On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
    • On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
  • Must be deemed appropriate for treatment with ET

  • If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression

  • Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)

  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)

  • Have adequate renal, hematologic, and hepatic organ function

  • Must be able to swallow capsules/tablets

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
  • Have symptomatic or untreated central nervous system metastasis
  • Have received any systemic therapy between disease recurrence/progression and study screening
  • Have received more than 1 line of therapy for advanced or metastatic disease.
  • Have received prior chemotherapy for metastatic breast cancer (MBC)
  • Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A: Abemaciclib plus Fulvestrant

Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

Administered orally.

Administered IM.

Aktiv komparator: Arm B: Placebo plus Fulvestrant

Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

Administered IM.

Administered orally.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Tidsramme: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)

PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Tidsramme: Randomization until measured progressive disease (Up to 22 Months)

ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Randomization until measured progressive disease (Up to 22 Months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. marts 2022

Primær færdiggørelse (Faktiske)

8. februar 2024

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

22. december 2021

Først indsendt, der opfyldte QC-kriterier

22. december 2021

Først opslået (Faktiske)

27. december 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 18238
  • I3Y-MC-JPEF (Anden identifikator: Eli Lilly and Company)
  • 2021-002301-10 (EudraCT nummer)
  • 2023-506771-10-00 (Anden identifikator: EU Trial Number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD-delingstidsramme

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

IPD-delingsadgangskriterier

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .